Login / Signup
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
Mei Zhan
Hanrui Zheng
Yu Yang
Zhiyao He
Ting Xu
Qiu Li
Published in:
Cancer management and research (2020)
Compared with placebo, maintenance olaparib for metastatic pancreatic cancer patients with a germline BRCA mutation is not cost-effective in China.
Keyphrases
</>
phase iii
dna repair
squamous cell carcinoma
small cell lung cancer
clinical trial
breast cancer risk
study protocol
double blind
dna damage
randomized controlled trial
oxidative stress